DRUG STUDY

Nicardipine

Name of Classification of Mechanism of Action Indication Contraindications Side Effects Nursing

Drug Drug Responsibilitie

 Generic  Therapeutic:  Description: Used for the Do not use More common Before:

Name: Cardiovascula Nicardipine is a management of nicardipine in  Assess

 Blurred
Nicardipin r Agent dihydropyridine Ca patients with patients with blood
vision
e channel blocker. It chronic stable advanced aortic pressure
 confusion
 Pharmacolog inhibits Ca ion from angina and for stenosis because periodically
 dizziness,
 Brand ic: Calcium entering the slow the treatment of of the afterload and
faintness, or
name: Channel channels or select hypertension. reduction effect of compare to
lightheaded
Cardepin Blocking voltage-sensitive nicardipine. normal
ness when
e Agents areas of vascular Reduction of values to
getting up
 smooth muscle and diastolic pressure from a lying help

 Dosage myocardium during in these patients or sitting document

given: depolarisation, may worsen rather position antihyperte

10 mg /10 producing a relaxation than improve suddenly nsive

mL of coronary vascular myocardial oxygen  sweating effects.

solution in smooth muscle and balance.  unusual  Monitor

a coronary tiredness or rashes or

single-us vasodilatation. It also weakness other skin

e vial increases myocardial Less common reactions

oxygen delivery in (hives,

 Bleeding,
 Route: patients w/ abnormal
blistering,
Intraveno vasospastic angina. sweating,
burning,
us  Pharmacokinetics: itching/burni
coldness,
a. Absorption: While ng,
 nicardipine is discoloratio exfoliation).

completely n of skin, Notify

absorbed, it is feeling of physician

subject to pressure, immediately

saturable first pass hives, because

metabolism and infection, certain skin

the systemic inflammatio reactions

bioavailability is n, itching, may

about 35% lumps, indicate

following a 30 mg numbness, serious

oral dose at steady pain, rash, hypersensiti

state. redness, vity

scarring, reactions

b. Time to peak soreness, (Stevens-Jo

 plasma stinging, hnson

concentration: swelling, syndrome).

Immediate-release tenderness,  Assess if

cap: 30-120 min; tingling, the patient

sustained-release ulceration, has any

cap: 60-240 min. or warmth hepatic or

at site renal

 blood in impairment.

urine
 Distribution: 8.3
 chills During:
L/kg
 cold sweats  Ensure that
 Plasma protein
 convulsions it is given to
binding: >95%
 decreased the right

urine patient with

  dry mouth the right

 Metabolism:  extra dose amd

Nicardipine HCl is heartbeat right route.

metabolized  fast,

extensively by the pounding, After:

liver. or irregular  Assess

heartbeat or peripheral

 Excretion: pulse edema

Nicardipine has been  frequent using girth

shown to be rapidly urination measureme

and extensively  increased nts, volume

metabolized by the thirst displaceme

liver.  increased nt, and

 Elimination half-life: volume of measureme

 8.6 hours pale, dilute nt of pitting

urine edema.

 Therapeutic  irregular Report

Effect(s): Significantly heartbeat increased

decreases systemic  loss of swelling in

vascular resistance. It appetite feet and

reduces BP at rest  mood ankles due

and during isometric changes to

and dynamic exercise.  muscle pain peripheral

or cramps vasodilation

 nausea or .

vomiting  Monitor IV

 numbness injection

or tingling in site for pain,

 hands, feet, swelling,

or lips and

 shortness of irritation.

breath Report

prolonged

or

excessive

injection

site

reactions to

the

physician.

 Evaluate

the
effectivenes

s of the

drug and

report or

document it

immediately

.
 Trimetazidine Hydrochloride

Name of Classification of Mechanism of Action Indication Contraindications Side Effects Nursing

Drug Drug Responsibilities

 Generic  Therapeutic:  Description: For the Do not take  Nausea, Before:

Name: Anti-anginal Trimetazidine inhibits prophylactic Trimetazidine vomiting  Followed the 14

Trimetazi β-oxidation of fatty treatment of Hydrochloride  Abdomina Rights of Drug

dine acids by blocking episodes of (TMZ-MR) if l pain, Administration.

hydrochlo long-chain angina pectoris, allergic to any of indigestio  Patient’s name

ride 3-ketoacyl-CoA thiola adjuvant the constituents. n was checked

 Brand se, with the effect of symptomatic This drug is  Diarrhoea through the

Name: enhancing glucose treatment of generally not  Dizziness identification band.

TMZ oxidation, resulting in vertigo and recommended  Headache , self was introduced.

more efficient tinnitus and during breast  Feeling  Stated what the

production of ATP adjuvant feeding. weak medication is and

 Dosage with less oxygen treatment of the  Rashes what it is for.

given: 35 demand. It prevents a decline in visual  Trembling  Took the patient’s

mg decrease in acuity and  Unsteady blood pressure

intracellular ATP visual field gait before giving. It

levels by preserving disturbances  Uncontroll must not be given

 Route: energy metabolism in presumably of ed body if hypotension is

Oral cells exposed vascular origin movemen present.

to ischaemia or t  If conscious,

hypoxia, thus  Swollen Inform patient that

ensuring the proper face/eyes/ drug

functioning of ionic lips/tongu may cause heada

pumps and e che.

transmembrane Na-K  Difficulty  If conscious,

flow without in instruct patient to

 changing haemodyna breathing move slowly when

micparameters.  Itchy skin sitting up or

rashes standing, to avoid

 Pharmacokinetics: over your dizziness or

whole light-headeness

a. Absorption: In body from sudden blood

elderly patients, a pressure

35 mg oral decrease.

modified release

tablet reaches a During:

mean Cmax of 115  Make sure that

µg/L, with a Tmax of the patient had

2.0-5.0 hours, and eaten already

a mean AUC0-12 of his/her food before

 1104 h*µg/L. In administer the

young, healthy medication.

patients, the same

dose reaches a After:

mean Cmaxof 91.2  Observe for any

µg/L, with a Tmax of signs of side

2.0-6.0 hours, and effects or adverse

an AUC0-12h 720 reactions.

h*µg/L.  Evaluate the

b. Time to peak effectiveness of the

plasma drug and report or

concentration: document it

 Distribution: 4.8 L/kg immediately.

 Plasma protein

binding: 15%

 Metabolism:

Trimetazidine can be

oxidized at the

piperazine ring to form

trimetazidine

ketopiperazine. Trimet

azidine can also be

N-formylated,

N-acetylated, or

N-methylated at the

piperazine ring to form

N-formyltrimetazidine,

N-acetyltrimetazidine,

and

N-methyltrimetazidine

respectively.

Alternatively,

trimetazidine can be

demethylated at the 2,

3, or 4 position of the

2,3,4-trimethoxybenzyl

moiety to form

2-desmethyltrimetazid

ine,

3-desmethyltrimetazid
 ine, or

4-desmethyltrimetazid

ine. The

desmethyltrimetazidin

e metabolites can

undergo sulfate

conjugation or

glucuronidation prior

to elimination.

 Excretion: 79-84%

eliminated in the

urine, with 60% as the

unchanged parent

compound.
 Elimination half-life: In

young, healthy

subjects, the half life

of trimetazidine is 7.81

hours. In patients over

65, the half life

increases to 11.7

hours.

 Therapeutic Effect(s):

Relief and prevention

of angina pectoris